Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05014893
Other study ID # 201900045
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 6, 2021
Est. completion date December 31, 2026

Study information

Verified date January 2024
Source National Research Center for Rehabilitation Technical Aids
Contact Ying Wang
Phone 1058122921
Email CARM_AD@aliyun.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates the neural mechanisms of cognitive function decline, cognitive assessment methods for subjects with mild cognitive dysfunction (Mild cognitive impairment, MCI, or cognitive decline milder than MCI), and the approaches used to improve and restore cognitive function.


Description:

Cognitive assessment tools are used to assess cognitive function of subjects in different cities. Functional and structural MRI and EEG are applied to investigate the neural mechanisms of cognitive function decline and effects of methods to improve and restore cognitive function.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults being able to walk at least a block, and - Adults with subjective cognitive decline (SCD), or - Adults with mild cognitive impairment (MCI), or - Adults with normal cognitive function Exclusion Criteria: - Clinical diagnosis of dementia - Adults who cannot follow the protocal

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
multi-modal targeted intervention (e.g., cognitive training, exercise, games)
The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)

Locations

Country Name City State
China National Research Center for Rehabilitation Technical Aids Beijing Beijing

Sponsors (6)

Lead Sponsor Collaborator
National Research Center for Rehabilitation Technical Aids Beijing academy of science and technology, Beijing University of Chinese Medicine, Central South University, Nanjing Brain Hospital, The Third People's Hospital of Yunnan Province

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. Up to 24 months.
Primary Change in Cognitive function (SCD-9) The SCD-9 questionnaire is used to assess cognitive function of participants. Change from Baseline Cognitive test results at 3 months.
Primary Change in Cognitive function (MoCA) The Montreal Cognitive Assessment test is used to assess cognitive function of participants. Change from Baseline Cognitive test results at 3 months.
Primary Change in Cognitive function (AD8) The AD8 test is used to assess cognitive function of participants. Change from Baseline Cognitive test results at 3 months.
Primary Change in Cognitive function (CDR) The Clinical Dementia Rating (CDR) test is used to assess cognitive function of participants. Change from Baseline Cognitive test results at 3 months.
Secondary Change in Physical capacity (TUG) The timed up and go (TUG) test is used to evaluate physical capacity of participants. Change from Baseline physical capacity test results at 3 months.
Secondary Change in Physical capacity (chair standing) The 30-second chair standing test is used to evaluate physical capacity of participants. Change from Baseline physical capacity test results at 3 months.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1